Windtree Therapeutics, Inc. (WINT)
| Market Cap | 60.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -62.82M |
| Shares Out | 26.35M |
| EPS (ttm) | -3.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 188,479 |
| Open | 2.28 |
| Previous Close | 2.28 |
| Day's Range | 2.26 - 2.30 |
| 52-Week Range | 1.58 - 7.53 |
| Beta | -0.07 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+360.5%) |
| Est. Earnings Date | Nov 4, 2021 |
About WINT
Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in pr...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for WINT stock is "Strong Buy" and the 12-month stock price forecast is 10.50.
News
Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming D...
Tuesday, October 19th @ 8:00 am Eastern Time Tuesday, October 19th @ 8:00 am Eastern Time
Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Trea...
Cardiogenic Shock Worldwide Total Market Value Is Estimated To Be $1.25 Billion Cardiogenic Shock Worldwide Total Market Value Is Estimated To Be $1.25 Billion
Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
WARRINGTON, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for ac...
Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acu...
Windtree to Present at Access to Giving Virtual Investor Conference
WARRINGTON, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acu...
Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)
WARRINGTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acu...
Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel
WARRINGTON, Pa., July 1, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute ca...
Meme Penny Stocks, What Are They, and 3 to Watch Right Now
Meme penny stocks are in focus right now, what are they, and which small-caps are investors watching? The post Meme Penny Stocks, What Are They, and 3 to Watch Right Now appeared first on Penny Stocks t...
Why Windtree Therapeutics Stock Is Moving Today
Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher by 32% at $2.63 in Friday's premarket session after Oppenheimer initiated coverage on the stock with an Outperform rating and an $8 pric...
Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., May 13, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute ca...
Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent
WARRINGTON, Pa., April 19, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-...
2 Falling Knives to Catch
Wall Street recommends buying shares of NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) and Windtree Therapeutics Inc (NASDAQ:WINT), even though these two securities have shown poor performance over the prior...
Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., March 29, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute ...
Windtree Therapeutics Announces Closing of $30.0 Million Public Offering
WARRINGTON, Pa., March 25, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-...
Windtree Therapeutics Announces Pricing of $30.0 Million Public Offering
WARRINGTON, Pa., March 23, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-...
Windtree Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
WARRINGTON, Pa., March 22, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-...
Windtree Therapeutics' AEROSURF Drug Delivery Device Secures US Patent
United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,874,818 to Windtree Therapeutics Inc (NASDAQ: WINT), covering features of the aerosol delivery system for AEROSURF drug de...
Windtree Therapeutics Reports Third Quarter 2020 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 16, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute c...
Windtree Therapeutics Reports Second Quarter 2020 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical devi...
Why Windtree Therapeutics Shares Are Trading Higher Today
Windtree Therapeutics Inc (NASDAQ: WINT) shares are trading higher on Wednesday. The company announced the initial European trial sites activated for its AEROSURF Bridging study and a collaboration for ...